AR038426A1 - Composicion de liberacion colonica - Google Patents

Composicion de liberacion colonica

Info

Publication number
AR038426A1
AR038426A1 ARP030100480A ARP030100480A AR038426A1 AR 038426 A1 AR038426 A1 AR 038426A1 AR P030100480 A ARP030100480 A AR P030100480A AR P030100480 A ARP030100480 A AR P030100480A AR 038426 A1 AR038426 A1 AR 038426A1
Authority
AR
Argentina
Prior art keywords
amylose
colonic
liberation
composition
ethyl cellulose
Prior art date
Application number
ARP030100480A
Other languages
English (en)
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of AR038426A1 publication Critical patent/AR038426A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una formulación de liberación controlada (preferentemente retardada) mejorada para la administración de metasulfobenzoato sódico de prednisolona. La formulación comprende metasulfobenzoato sódico de prednisolona rodeado por un recubrimiento que comprende amilosa vítrea, etilcelulosa y sebacato dibutílico, en donde la relación de amilosa a etilcelulosa es de 1:3,5 a 1:4,5 y en donde la amilosa es amilosa de trigo ó maíz.
ARP030100480A 2002-02-13 2003-02-13 Composicion de liberacion colonica AR038426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0203421.3A GB0203421D0 (en) 2002-02-13 2002-02-13 Composition

Publications (1)

Publication Number Publication Date
AR038426A1 true AR038426A1 (es) 2005-01-12

Family

ID=9931006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100480A AR038426A1 (es) 2002-02-13 2003-02-13 Composicion de liberacion colonica

Country Status (14)

Country Link
US (1) US20050220861A1 (es)
EP (1) EP1474116A1 (es)
JP (1) JP2005521682A (es)
CN (1) CN100350913C (es)
AR (1) AR038426A1 (es)
AU (1) AU2003212491B2 (es)
CA (1) CA2475704C (es)
GB (1) GB0203421D0 (es)
MX (1) MXPA04007894A (es)
MY (1) MY137423A (es)
RU (1) RU2327446C2 (es)
TW (1) TWI291354B (es)
WO (1) WO2003068196A1 (es)
ZA (1) ZA200406397B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CA2658915A1 (en) * 2006-07-27 2008-01-31 University Of Sunderland Coating composition comprising starch
CA2683415C (en) 2007-04-04 2020-12-08 Sigmoid Pharma Limited An oral pharmaceutical composition
ES2425762T3 (es) 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
LT2659881T (lt) 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
TN2016000119A1 (en) 2013-10-29 2017-10-06 Tillotts Pharma Ag A delayed release drug formulation
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662902A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
ATE211610T1 (de) * 1992-07-31 2002-01-15 Goodman Fielder Ltd Stärke mit hohem amylose-gehalt und resistenten stärke-fraktionen
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
GB9722426D0 (en) * 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) * 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.

Also Published As

Publication number Publication date
RU2004127867A (ru) 2005-06-10
RU2327446C2 (ru) 2008-06-27
WO2003068196A1 (en) 2003-08-21
CN1638746A (zh) 2005-07-13
MY137423A (en) 2009-01-30
AU2003212491B2 (en) 2008-04-17
GB0203421D0 (en) 2002-04-03
AU2003212491A1 (en) 2003-09-04
CN100350913C (zh) 2007-11-28
MXPA04007894A (es) 2004-10-15
TWI291354B (en) 2007-12-21
US20050220861A1 (en) 2005-10-06
CA2475704C (en) 2011-07-12
EP1474116A1 (en) 2004-11-10
ZA200406397B (en) 2005-09-12
CA2475704A1 (en) 2003-08-21
JP2005521682A (ja) 2005-07-21
TW200302744A (en) 2003-08-16

Similar Documents

Publication Publication Date Title
AR038426A1 (es) Composicion de liberacion colonica
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
IL155071A (en) History of glucopyranosyloxybenzylbenzene and their use and pharmaceutical preparations containing them
BRPI0409334A (pt) pelìcula de gel termorreversìvel, homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e cápsulas moles, e, forma sólida
TW200740427A (en) Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
WO2005112635A3 (en) Uridine effects on dopamine release
NO20050771L (no) Bicifadinformulering
AU2003259789A1 (en) High concentration surfactant compositions and methods
GB2388778B (en) Method and composition for combatting pesticide resistance
HRP20041013B1 (hr) Formulacija visoke doze ibandronata
GB0113403D0 (en) Tablet enrobing
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL350419A1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
MY140127A (en) Pharmaceutical formulation
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20054157L (no) Formuleringer av venlafaksin med forsinket frigjoring
NO20071977L (no) Stabilisert farmasoytisk formulering av leukotrien b4 (ltb4)-middel
GB0522474D0 (en) A pharmaceutical formulation
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
EA200500613A1 (ru) Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция
BR0215806A (pt) Composição oral de telitromicina com paladar mascarado

Legal Events

Date Code Title Description
FB Suspension of granting procedure